$PRVA

Morris Matthew Shawn sold $3.8M of PRVA

Morris Matthew Shawn sold 151,322 shares of Privia Health Group, Inc. (PRVA) at $25.33 ($3.83M total) across 2 trades over 2026-06-26 to 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Morris Matthew Shawn
Published Jun 30, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
medium confidence
Mentioned
$PRVA
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The only new information is the disclosed sale size, price ($25.33), trade dates, and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Insider selling disclosure can influence short-term sentiment, but 10b5-1 status reduces interpretability as a negative fundamental signal.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is typically weak.

Relevance 5/10Novelty 4/10Timing: Filed 2026-06-30 after trades dated 2026-06-26 to 2026-06-29.

Background

The filing is an SEC Form 4 insider transaction for Privia Health Group, Inc., reported by a director.

Company-level read

Ticker impact

$PRVANeutralMedium confidence
Context

Privia Health Group director Morris Matthew Shawn sold 151,322 shares in open-market trades at $25.33 (10b5-1 plan disclosed).

Expected impact

Likely limited near-term impact; any reaction should be muted given 10b5-1 pre-arrangement.

Evidence & confidence

Form 4 provides transaction size, price, and 10b5-1 status, but no new company performance, guidance, or deal information.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

No meaningful regional impact indicated.

No global market relevance indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Privia Health Group, Inc.

    Issuer of the Form 4 insider sale; director sold 151,322 shares at $25.33.

  • Morris Matthew Shawn

    Director who executed open-market sales under a Rule 10b5-1 plan.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for